These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 15345892)
21. Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer. Andreopoulou E; Chen T; Liebes L; Curtin J; Blank S; Wallach R; Hochster H; Muggia F Cancer Chemother Pharmacol; 2011 Aug; 68(2):457-63. PubMed ID: 21069334 [TBL] [Abstract][Full Text] [Related]
22. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL). Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814 [TBL] [Abstract][Full Text] [Related]
23. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma. Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920 [TBL] [Abstract][Full Text] [Related]
24. Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy. Huisman C; Biesma B; Postmus PE; Giaccone G; Schramel FM; Smit EF Br J Cancer; 2001 Nov; 85(10):1456-61. PubMed ID: 11720428 [TBL] [Abstract][Full Text] [Related]
25. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases]. Fan Y; Huang ZY; Luo LH; Yu HF Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458 [TBL] [Abstract][Full Text] [Related]
26. Sequence-dependent hematologic side effects of topotecan and cisplatin in persistent or recurrent cervical cancer. Lee YY; Lee JW; Park HS; Song TJ; Kim MK; Choi CH; Kim TJ; Lee JH; Bae DS; Kim BG Gynecol Oncol; 2010 Oct; 119(1):87-91. PubMed ID: 20580417 [TBL] [Abstract][Full Text] [Related]
27. [Vindesine, CCNU, high-dosage ara-C, and prednisolone (VINAP regimen) in the treatment of relapsing or refractory non-Hodgkin's lymphomas]. Domingo Albós A; Callís M; Juliá A; Vilá J; Zuazu J; Puig J; Petit J; Fernández-Sevilla A Sangre (Barc); 1989 Apr; 34(2):107-11. PubMed ID: 2756450 [TBL] [Abstract][Full Text] [Related]
28. [Bendamustine, vincristine, prednisolone (BOP) in therapy of advanced low-grade non-Hodgkin lymphoma]]. Kath R; Blumenstengel K; Fricke HJ; Peters HD; Höffken K Dtsch Med Wochenschr; 2001 Feb; 126(8):198-202. PubMed ID: 11256023 [TBL] [Abstract][Full Text] [Related]
29. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721 [TBL] [Abstract][Full Text] [Related]
30. A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer. Lu C; Komaki R; Lee JS; Shin DM; Palmer JL; Coldman BJ; Pisters KM; Kurie JM; Fossella FV; Glisson BS Clin Cancer Res; 2003 Jun; 9(6):2085-91. PubMed ID: 12796372 [TBL] [Abstract][Full Text] [Related]
31. Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma. Ho AD; Del Valle F; Haas R; Engelhard M; Hiddemann W; Rückle H; Schlimok G; Thiel E; Andreesen R; Fiedler W Semin Oncol; 1990 Dec; 17(6 Suppl 10):14-8; discussion 18-9. PubMed ID: 2259918 [TBL] [Abstract][Full Text] [Related]
32. Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial. Lorusso V; Gebbia V; Spada M; Guida M; Cassano G; Brunetti C; Germano D; Nettis G; Izzi G; Galetta D; Giampaglia M; Silvestris N; Colucci G Oncol Rep; 2005 Dec; 14(6):1547-51. PubMed ID: 16273254 [TBL] [Abstract][Full Text] [Related]
33. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma. Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091 [TBL] [Abstract][Full Text] [Related]
34. A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation. Lee CK; de Magalhaes-Silverman M; Hayashi M; Schlueter A; Strauss RG; Hohl RJ; Gingrich RD Bone Marrow Transplant; 2002 Apr; 29(8):647-52. PubMed ID: 12180108 [TBL] [Abstract][Full Text] [Related]
35. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy. Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397 [TBL] [Abstract][Full Text] [Related]
36. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy. Dabaja BS; McLaughlin P; Ha CS; Pro B; Meyers CA; Seabrooke LF; Wilder RB; Kyritsis AP; Preti HA; Yung WK; Levin V; Cabanillas F; Cox JD Cancer; 2003 Sep; 98(5):1021-8. PubMed ID: 12942571 [TBL] [Abstract][Full Text] [Related]
37. Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Younes A; Preti HA; Hagemeister FB; McLaughlin P; Romaguera JE; Rodriguez MA; Samuels BI; Palmer JL; Cabanillas F Ann Oncol; 2001 Jul; 12(7):923-7. PubMed ID: 11521796 [TBL] [Abstract][Full Text] [Related]